| Myasthenia Gravis |
1 |
1 |
| Child |
0 |
0.99 |
| Muscular Atrophy |
0 |
0.8 |
| Toxicology |
0 |
0.47 |
| Biologic Therapy |
0 |
0.36 |
| Patient Safety |
0 |
0.26 |
| Adverse Effects |
0 |
0.2 |
| Orbit |
0 |
0.2 |
| Vaccines |
0 |
0.17 |
| Antineoplastic Drug |
0 |
0.13 |
| Glucocorticoid |
0 |
0.13 |
| Immunotherapy |
0 |
0.13 |
| Monoclonal Antibody |
0 |
0.13 |
| Intravenous Immunoglobulin (IVIG) |
0 |
0.11 |
| Accomodation |
0 |
0.07 |
| Acetylcholinesterase Inhibitor |
0 |
0.07 |
| Adherence |
0 |
0.07 |
| Adolescent Medicine |
0 |
0.07 |
| Bone |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| Gland |
0 |
0.07 |
| Hand |
0 |
0.07 |
| Immunocompromise |
0 |
0.07 |
| Immunoglobulin A (IgA) |
0 |
0.07 |
| Interference |
0 |
0.07 |
| Intravenous |
0 |
0.07 |
| Muscle |
0 |
0.07 |
| Ohio |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Steroids |
0 |
0.07 |
| Thymus |
0 |
0.07 |
| Weakness |
0 |
0.07 |
| Healthcare and Medical Technology |
0 |
0.06 |
| Weight Management |
0 |
0.06 |